Asthma medications and their potential adverse effects in the elderly: Recommendations for prescribing

Drug Safety

Volumn 24, Issue 14, 2001, Pages 1065-1080

  Newnham, Donald Mackenzie ^a  

^a WOODEND HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BAMBUTEROL; BECLOMETASONE; BENZTHIAZIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; MACROLIDE; POTASSIUM SPARING DIURETIC AGENT; SALBUTAMOL; SALMETEROL; SPIRONOLACTONE; TERBUTALINE; THEOPHYLLINE DERIVATIVE;

ASTHMA; BONE ATROPHY; CANDIDIASIS; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONOTROPISM; DOSE RESPONSE; DRUG POTENTIATION; HUMAN; HYPOKALEMIA; METERED DOSE INHALER; NAUSEA; OSTEOLYSIS; POLYPHARMACY; POTASSIUM DEPLETION; PRIORITY JOURNAL; PURPURA; QUALITY OF LIFE; REVIEW; TACHYCARDIA; TREMOR; VOMITING; XEROSTOMIA;

EID: 0035672636     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124140-00005     Document Type: Review

References (144)

1. Risk factors in geriatric drug prescribing: A practical guide to avoiding problems
2. Comparing sources of drug data about the elderly
3. Adverse drug reactions
4. Drug related admissions to medical wards: A population based survey
5. Drug related problems in elderly patients admitted to Tayside Hospitals, methods for prevention and subsequent re-assessment
6. Contribution of adverse drug reactions to hospital admission of older patients
7. Drug related illness resulting in hospital admission
8. Drug induced illness as a cause for admission to a community hospital
9. Adverse reactions to prescribed drugs in the elderly: A multicentre investigation
10. Prescription of contra-indicated and interacting drugs in elderly patients admitted to hospital
11. Iatrogenic disease in general practice: Its incidence and effects
12. Preventable drug reactions: Causes and cures
13. Drug related hospital admissions
14. Under-reporting of adverse drug reactions: Estimate based on a spontaneous reporting scheme and a sentinel system
15. A population survey of respiratory symptoms in the elderly
16. The prevalence of adult onset wheeze: Longitudinal study
17. Prevalence and treatment of chronic airways obstruction in adults over the age of 45
18. Polypharmacy: Correlations with sex, age and drug regimen. A prescription database study
19. Montelukast for chronic asthma in 6 to 14 year old children
20. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma; a multicentre, randomised double-blind trial
21. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild to moderate asthma: A randomised, double blind, placebo controlled trial
22. Oral montelukast, inhaled beclomethasone and placebo for chronic asthma
23. Effects of antileukotrienes in the treatment of asthma
24. Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects
25. Comparison of beta-adrenoceptor responsiveness following prolonged treatment with low and high doses of inhaled terbutaline in chronic obstructive lung disease
26. Influence of age on response to ipratropium and salbutamol in asthma
27. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis
28. Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma
29. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects
30. Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear-shaped spacer attachment: Comparison of electrocardiographic, hypokalaemic and haemodynamic effects
31. Salbutamol causes a tachycardia due to the inhaled rather than the swallowed fraction
32. Systemic cardiovascular and metabolic effects associated with the inhalation of an increased dose of albuterol: Influence of mouth rinsing and gargling
33. Pharmacokinetics of inhaled substances
34. Deposition of pressurised aerosols in the human respiratory tract
35. Improvement of pressurised aerosol deposition with Nebuhaler spacer device
36. Comparison of the extrapulmonary beta-2 adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose inhaler and modified actuator device
37. Inhaler technique in the elderly
38. Problems elderly patients have using metered dose inhalers
39. Inhaler technique of elderly patients: Comparison of metered-dose inhalers and large volume spacer devices
40. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction
41. Tachyphylaxis to systemic but not airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics
42. Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low-dose inhaled salbutamol
43. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma
44. Subsensitivity of bronchodilator and systemic beta-2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients
45. Effect of prednisolone and ketotifen on beta-2 adrenoceptors in asthmatic patients receiving beta-2 bronchodilators
46. Effects of inhaled beclomethasone dipropionate on beta-2 receptor function in the airways and adrenal responsiveness in bronchial asthma
47. 2-agonist therapy
48. Hypokalaemia from beta-2 receptor stimulation by circulating epinephrine
49. Evaluation of the metabolic responses to inhaled salbutamoI in the measurement of beta-2 adrenoceptor blockade
50. Effect of potassium and calcium deficiency on the monophasic action potential, electrocardiogram and contractility of isolated rabbit hearts
51. Effects of low potassium or magnesium concentrations on isolated cardiac muscle
52. Electrophysiologic characteristics of human ventricular and Purkinje fibres
53. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction
54. Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease
55. Cardiac arrhythmias caused by nebulised beta-agonist therapy
56. Cardiopulmonary effects of fenoterol and salbutamol aerosols
57. The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic responses to inhaled terbutaline
58. Salbutamol induced hypokalaemia: The effect of theophylline alone and in combination with adrenaline
59. Prior treatment with diuretic augments the hypokalaemic and electrocardiographic effects of inhaled albuterol
60. Hypokalaemic and ECG sequelae of combined beta-agonist/diuretic therapy: Protection by conventional doses of spironolactone but not triamterene
61. Relation between electrocardiogram and electrolytes
62. The Q-T interval
63. Serum potassium and the electrocardiograph and hypokalaemia
64. Long Q-T: Good, bad or indifferent?
65. Reflex vagal withdrawal and the haemodynamic response to intravenous isoproterenol in the presence of beta-agonists
66. Intracoronary injections of salbutamol demonstrate the presence of functional beta-2 adrenoceptors in the human heart
67. Assessment of airways, tremor andchronotropic responses to inhaled salbutamol in the quantification of beta-2 adrenoceptor blockade
68. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol and isoprenaline
69. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: A placebo-controlled dose-response study in healthy volunteers
70. Prescribed fenoterol and death from asthma in New Zealand. 1981-1983: Case-control study
71. Single dosing comparison of the relative cardiac beta-1/beta-2 activity of inhaled fenoterol and salbutamol in normal subjects
72. A dose-ranging study to evaluate the beta-1 adrenoceptor selectivity of bisoprolol
73. Low prevalence of postural hypotension among community dwelling elderly
74. Older subjects show no age-related decrease in cardiac baroreceptor sensitivity
75. A measure of quality of life for clinical trials in chronic lung disease
76. Prednisolone (meticorten) in the treatment of bronchial asthma: Clinical study
77. Controlled trial of effects of cortisone acetate in chronic asthma
78. Controlled trial of effects of cortisone acetate in status asthmaticus
79. Dosages of corticosteroids in asthma
80. Corticosteroids in asthma: Rationale, use and problems
81. A controlled study of the effects of single doses of hydrocortisone on the resolution of acute attacks of asthma
82. The time course of response to prednisolone in chronic bronchial asthma
83. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma
84. What role for inhaled steroids in chronic asthma?
85. British guidelines on asthma management: 1995 review and position statement
86. A comparison of oral and inhaled steroids in patients with chronic airways obstruction: Features determining response
87. Steroid response in stable chronic airflow obstruction
88. Corticosteroids in COPD. A clinical trial and reassessment of the literature
89. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease
90. Pharmacokinetic optimisation of inhaled steroid therapy in asthma
91. Dosing regimen of budesonide and occurrence of oropharyngeal complications
92. Aerosol corticosteroids for the treatment of asthma
93. Safety of HFA-134a beclomethasone dipropionate extra fine aerosol
94. Efficiency and safety of inhaled corticosteroids in asthma
95. A comparison of the efficacy and safety of inhaled corticosteroids in asthma
96. Dose-response of inhaled drugs in asthma: An update
97. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetic absorption
98. Systemic effects of high dose inhaled steroids: Comparison of beclomethasone dipropionate and budesonide in healthy subjects
99. Glucocorticosteroids and asthma-studies of resistance and systemic effects of glucocorticosteroids
100. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for 1 year
101. Use of spacers to facilitate inhaled corticosteroid treatment of asthma
102. HFA-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to CFC beclomethasone dipropionate at approximately half the total daily dose
103. Decreased bone mineral density in pre-menopausal asthma patients receiving long-term inhaled steroids
104. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids
105. Beclomethasone inhalation decreases serum osteocalcin concentrations
106. Effects of dose and dosing schedules of inhaled budesonide on bone turnover
107. Bone turnover during high dose inhaled corticosteroid treatment
108. High dose fluticasone propionate l mg daily versus fluticasone propionate 2mg daily or budesonide 1.6mg daily in patients with severe chronic asthma
109. Effects of short term exposure to inhaled corticosteroids on novel biochemical makers of bone metabolism
110. Purpura and dermal thinning associated with high dose inhaled corticosteroids
111. Easy bruising as a side-effect of inhaled corticosteroids
112. Association of ocular cataracts with inhaled and oral steroid therapy during long term treatment of asthma
113. Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500μg per day) and budesonide (1600μg per day) for chronic asthma
114. Plasma theophylline concentrations, six minute walking distances and breathlessness in patients with chronic air flow obstruction
115. Effects of theophylline on breathlessness and exercise tolerance in patients with chronic airflow obstruction
116. Dose response relation to oral theophylline in severe chronic obstruction airways disease
117. Activities of caffeine, theophylline and enprofylline analogs as tracheal relaxants
118. Aminophylline improves diaphragm contractability
119. Comparative natiuretic and diuretic efficacy of theophylline, ethylenediamine and of bendroflumethazide during long term treatment with the potent diuretic bumetanide. Permutation trial tests in patients with congestive heart failure
120. Theophylline toxicity: Clinical features of 116 consecutive cases
121. Evaluation of theophylline overdoses and toxicities
122. Hospital admission for xanthine toxicity
123. Theophylline
124. Effects of passive smoking on theophylline clearance
125. Effects of oral theophylline and oral salbutamol in the treatment of asthma
126. Asthma: A possible interaction between hydrocortisone and theophylline
127. Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction
128. Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: Influence of erythromycin
129. A case of acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin
130. Comparison of the anti-cholinergic bronchodilator ipratropium bromide with metaproteranol in chronic obstructive pulmonary disease
131. Comparative trial of a new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis
132. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease
133. Combination bronchodilator therapy in asthma
134. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD
135. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease
136. Effect of four weeks high dose ipratropium bromide treatment on lung mucociliary clearance
137. Bronchoconstriction in response to ipratropium bromide
138. Muscarinic receptor agonists and antagonists
139. A comparison of the bronchodilating effects of oxitropium bromide and fenoterol in patients with chronic obstructive pulmonary disease